ArticleThe Journal of infectious diseases2019
Impact of Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Dual Infection on Female Genital Tract Mucosal Immunity and the Vaginal Microbiome.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- HSV, HIV, and Pregnancy: Epidemiology, Viral Interactions, Management, and Prevention.Current HIV/AIDS reports · 2026Review
- Herpes Simplex Virus Type 2 Screening in Persons with and Without HIV: Evidence, Challenges, and Future Directions.Current HIV/AIDS reports · 2026Review
- Developments in genital herpes: progress in prevention and treatment.Current opinion in infectious diseases · 2026Review
- Vaginal Microbiota Dysbiosis and Infections: A Comprehensive Review of Microbial and Therapeutic Perspectives.International journal of women's health · 2026Review
- Cervicovaginal Secretions in Young Women With Bacterial Vaginosis Enhance HIV Infection.The Journal of infectious diseases · 2025Article
- Immune horses rapidly increase antileukoproteinase and lack type I interferon secretion during mucosal innate immune responses against equine herpesvirus type 1.Microbiology spectrum · 2024Article
- The vaginal microbiome of transgender men receiving gender-affirming hormonal therapy in comparison to that of cisgender women.Scientific reports · 2024Article
- Sexually Transmitted Infections in People with Human Immunodeficiency Virus.Infectious disease clinics of North America · 2024Review
- HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal.The Journal of clinical investigation · 2023Article
- Defensins: defenders of human reproductive health.Human reproduction update · 2023Review
- The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments.Journal of microbiology and biotechnology · 2022Review
- Role of the human vaginal microbiota in the regulation of inflammation and sexually transmitted infection acquisition: Contribution of the non-human primate model to a better understanding?Frontiers in reproductive health · 2022Review
- Effects of SARS-CoV-2 infection on human reproduction.Journal of molecular cell biology · 2021Review
- Review
- Article
- Tissue Microbiome Associated With Human Diseases by Whole Transcriptome Sequencing and 16S Metagenomics.Frontiers in genetics · 2021Review
- Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19.Microbial cell factories · 2020Review
- Vaccines to prevent genital herpes.Translational research : the journal of laboratory and clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundMechanisms linking herpes simplex virus type 2 (HSV-2) with human immunodeficiency virus (HIV) are not fully defined. We tested the hypothesis that HSV-2 and HIV dual infection is associated with cervicovaginal inflammation and/or vaginal dysbiosis.
methodsGenital tract samples were obtained weekly over a 12-week period from 30 women seropositive (+) for HIV and HSV-2 and 15 women each who were seropositive for one or seronegative (-) for both viruses. Immune mediators, antimicrobial activity, and microbial composition and diversity were compared.
resultsSignificant differences in the concentrations of interferon-γ (P = .002), tumor necrosis factor-α (P = .03), human beta defensin 1 (P = .001), secretory leukocyte protease inhibitor (P = .01), and lysozyme (P = .03) were observed across the 4 groups (Kruskal-Wallis). There were also significant differences in vaginal microbial alpha diversity (Simpson index) (P = .0046). Specifically, when comparing HIV-1+/HSV-2+ to HIV-1-/HSV-2- women, a decrease in Lactobacillus crispatus and increase in diverse anaerobes was observed. The number of genital HSV outbreaks was greater in HIV+ versus HIV- women (39 versus 12) (P = .04), but there were no significant differences when comparing outbreak to non-outbreak visits.
conclusionsIncreased microbial diversity and cervicovaginal inflammation in HIV and HSV-2 dually infected women may adversely impact genital health and, in the absence of antiretroviral therapy, facilitate HIV shedding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.